Baclofen for alcohol dependence in France: Incidence of treated patients and prescription patterns-A cohort study

European Neuropsychopharmacology

Volumn 24, Issue 2, 2014, Pages 192-199

  Dupouy, Julie ^a   Fournier, Jean Pascal ^a   Jouanjus, Émilie ^a,b   Palmaro, Aurore ^a,b   Poutrain, Jean Christophe ^a   Oustric, Stéphane ^a   Lapeyre Mestre, Maryse ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Addictive behavior; Alcoholism; Baclofen; Cohort studies; General practitioners; Incidence

Indexed keywords

BACLOFEN;

ADULT; AGED; ALCOHOLISM; ARTICLE; COHORT ANALYSIS; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; FRANCE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROLOGIC DISEASE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADDICTIVE BEHAVIOR; ALCOHOLISM; BACLOFEN; COHORT STUDIES; GENERAL PRACTITIONERS; INCIDENCE;

ALCOHOLISM; BACLOFEN; DANTROLENE; EUROPE; FEMALE; FRANCE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; NERVOUS SYSTEM DISEASES; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84893670193     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.09.008     Document Type: Article

References (48)

1. Addolorato G., Caputo F., Capristo E., Domenicali M., Bernardi M., Janiri L., Agabio R., Colombo G., Gessa G.L., Gasbarrini G. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol and Alcoholism 2002, 37:504-508.
2. Addolorato G., Leggio L., Abenavoli L., Agabio R., Caputo F., Capristo E., Colombo G., Gessa G.L., Gasbarrini G. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. American Journal of Medicine 2006, 119:276.e13-276.e18.
3. Addolorato G., Leggio L., Ferrulli A., Cardone S., Bedogni G., Caputo F., Gasbarrini G., Landolfi R. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism 2011, 46:312-317.
4. Addolorato G., Leggio L., Ferrulli A., Cardone S., Vonghia L., Mirijello A., Abenavoli L., D'Angelo C., Caputo F., Zambon A., Haber P.S., Gasbarrini G. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007, 370:1915-1922.
5. Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol and Alcoholism 2005, 40:147-150.
6. Ameisen O. Le Dernier Verre 2008, Denoël, Paris.
7. Beck F., Guignard R., Obradovic I., Gautier A., Karila L. Increasing trends in screening for addictives behaviors among general practitioners in France. Revue d'Epidémiologie et de Santé Publique 2011, 59:285-294.
8. Blin P., Lassalle R., Dureau-Pournin C., Ambrosino B., Bernard M.A., Abouelfath A., Gin H., Le Jeunne C., Pariente A., Droz C., Moore N. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 2012, 55:644-653.
9. Bongue B., Laroche M.L., Gutton S., Colvez A., Guéguen R., Moulin J.J., Merle L. Potentially inappropriate drug prescription in the elderly in France: a population-based study from the French National Insurance Healthcare system. European Journal of Clinical Pharmacology 2011, 67:1291-1299.
10. Braillon A. Baclofen and protecting the patients during research. Alcohol and Alcoholism 2012, 47:631-632.
11. Charrel C.L., Cuervo-Lombard C.V., Miron M., Fruntes V., Béra-Potelle C., Limosin F. Alcohol dependence in women: difficulty of its assessment in general practice. Journal of Women's Health (Larchmt) 2010, 19:343-348.
12. ClinicalTrials.gov-a. Baclofen for the Treatment of Alcohol Drinkers. http://www.clinicaltrials.gov/ct2/show/NCT01604330term=bacloville&rank=1.
13. ClinicalTrials.gov-b. Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent Patients. http://www.clinicaltrials.gov/ct2/show/NCT01738282term=alpadir&rank=1.
14. Colombo G., Addolorato G., Agabio R., Carai M.A.M., Pibiri F., Serra S., Vacca G., Gessa G.L. Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotoxicity Research 2004, 6:403-414.
15. Colombo G., Agabio R., Carai M.A., Lobina C., Pani M., Reali R., Addolorato G., Gessa G.L. Ability of baclofen in reducing alcohol intake and withdrawal severity: I-Preclinical evidence. Alcoholism: Clinical and Experimental Research 2000, 24:58-66.
16. Colombo G., Serra S., Brunetti G., Vacca G., Carai M.A.M., Gessa G.L. Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend 2003, 70:105-108.
17. Comité Technique de Pharmacovigilance de mars 2012. Effets indésirables du baclofène dans le traitement des addictions. Suivi national de pharmacovigilance: année 2011. http://ansm.sante.fr/var/ansm_site/storage/original/application/264282cafe82f9e1f08323df4722fda1.pdf.
18. Davidoff R.A. Antispasticity drugs: mechanisms of action. Annals of Neurology 1985, 17:107-116.
19. de Beaurepaire R. Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients. Frontiers in Psychiatry 2012, 3:103.
20. Dore G.M., Lo K., Juckes L., Bezyan S., Latt N. Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comorbidity: a selected case series. Alcohol and Alcoholism 2011, 46:714-720.
21. Effertz T., Mann K. The burden and cost of disorders of the brain in Europe with the inclusion of harmful alcohol use and nicotine addiction. European Neuropsychopharmacology 2013, 23:742-748.
22. Evans S.M., Bisaga A. Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcoholism: Clinical and Experimental Research 2009, 33:19-30.
23. Fournier A., Zureik M. Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France. Pharmacoepidemiology and Drug Safety 2012, 21:343-351.
24. Frauger E., Pauly V., Pradel V., Rouby F., Arditti J., Thirion X., Lapeyre-Mestre M., Micallef J. Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network. Fundamental and Clinical Pharmacology 2011, 25:633-641.
25. Garbutt J.C., Kampov-Polevoy A.B., Gallop R., Kalka-Juhl L., Flannery B.A. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism: Clinical and Experimental Research 2010, 34:1849-1857.
26. Greene P. Baclofen in the treatment of dystonia. Clinical Neuropharmacology 1992, 15:276-288.
27. Journal Officiel de la République Française. Arrêté du 11 juillet 2012 relatif à la mise en oeuvre du système national d'information interrégimes de l'assurance maladie. <. http://www.legifrance.gouv.fr/affichTexte.docidTexte=JORFTEXT000026221180&dateTexte=&categorieLien=id.
28. Lapeyre-Mestre, M., Palmaro, A, 2011. Comparison of Utilization Data of Psychoactive Medications Having an Abuse Potential in the Different European Countries. Centre d'Evaluation et d'Information sur la Pharmacodépendence-Addictovigilance (CEIP-A). Available on specific request to the authors.
29. Leung N.Y., Whyte I.M., Isbister G.K. Baclofen overdose: defining the spectrum of toxicity. Emergency Medicine Australasia 2006, 18:77-82.
30. Liu J., Wang L. Baclofen for alcohol withdrawal. Cochrane Database of Systematic Reviews 2013, (CD008502).
31. Lyon J.E., Khan R.A., Gessert C.E., Larson P.M., Renier C.M. Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial. Journal of Hospital Medicine 2011, 6:469-474.
32. Macaigne G., Champagnon N., Harnois F., Cheiab S., Chayette C. Baclofen-induced acute hepatitis in alcohol-dependent patient. Clinics and Research in Hepatology and Gastroenterology 2011, 35:420-421.
33. Malet L., Llorca P.M., Boussiron D., Schwan R., Facy F., Reynaud M. General practitioners and alcohol use disorders: quantity without quality. Alcoholism: Clinical and Experimental Research 2003, 27:61-66.
34. Malet L., Reynaud M., Llorca P.M., Chakroun N., Blanc O., Falissard B. Outcomes from primary care management of alcohol dependence in France. Journal of Substance Abuse Treatment 2009, 36:457-462.
35. Muzyk A.J., Rivelli S.K., Gagliardi J.P. Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence. CNS Drugs 2012, 26:69-78.
36. Nasti J.J., Brakoulias V. Chronic baclofen abuse and withdrawal delirium. Australian and New Zealand Journal of Psychiatry 2011, 45:86-87.
37. Noize P., Bazin F., Dufouil C., Lechevallier-Michel N., Ancelin M.L., Dartigues J.F., Tzourio C., Moore N., Fourrier-Réglat A. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study. Pharmacoepidemiology and Drug Safety 2009, 18:310-319.
38. Pariente A., Pinet M., Moride Y., Merlière Y., Moore N., Fourrier-Réglat A. Factors associated with persistence of cholinesterase inhibitor treatments in the elderly. Pharmacoepidemiology and Drug Safety 2010, 19:680-686.
39. Rolland B., Bordet R., Cottencin O. Alcohol-dependence: the current French craze for baclofen. Addiction 2012, 107:848-849.
40. Rolland B., Deheul S., Danel T., Bordet R., Cottencin O. [A system of prescriptions without drug approval: example of baclofen.]. Therapie 2010, 65:511-518.
41. Rumpf H.J., Hapke U., Meyer C., John U. Screening for alcohol use disorders and at-risk drinking in the general population: psychometric performance of three questionnaires. Alcohol and Alcoholism 2002, 37:261-268.
42. Saddichha S., Jayaram N., Manjunatha N., Benegal V. Baclofen-induced morbiliform rashes: a case series. Journal of Clinical Pharmacology 2011, 51:1733-1734.
43. Shorter D., Kosten T.R. Novel pharmacotherapeutic treatments for cocaine addiction. BMC Medicine 2011, 9:119.
44. Smith C.R., LaRocca N.G., Giesser B.S., Scheinberg L.C. High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology 1991, 41:1829-1831.
45. Soufia M., Plaze M., Gueguen B., Demigneux G., Olié J.P., Gaillard R. Behavioral disinhibition with baclofen. Journal of Clinical Psychopharmacology 2010, 30:759-760.
46. Tiffany S.T., Wray J.M. The clinical significance of drug craving. Annals of the New York Academy of Sciences 2012, 1248:1-17.
47. Tuppin P., de Roquefeuil L., Weill A., Ricordeau P., Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Revue d'Epidémiologie et de Santé Publique 2010, 58:286-290.
48. Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Svensson M., Jönsson B., Olesen J., Allgulander C., Alonso J., Faravelli C., Fratiglioni L., Jennum P., Lieb R., Maercker A., van Os J., Preisig M., Salvador-Carulla L., Simon R., Steinhausen H.C. The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology 2011, 21:655-679.